Blood cancers

Podcast: Does ‘fit and unfit’ still fit with novel therapies in first-line CLL?

Sponsored by Janssen-Cilag Pty Ltd

The use of novel agents in first-line chronic lymphocytic leukaemia is changing the way we manage patients. In this podcast we continue the conversation with Professor Paolo Ghia, Associate Professor in Internal Medicine at the Università Vita-Salute San Raffaele and local haematologist, Professor Stephen Opat, a Member of the Monash Health Translation Precinct about the changes novel therapies ...

Already a member?

Login to keep reading.

© 2021 the limbic